Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 519

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Open access
Albiges, Laurence, Tannir, Nizar M., Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R., Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K., Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I., Choueiri, Toni K., Saggi, Shruti Shally, McHenry, M. Brent, Motzer, Robert J. · 2020 · ESMO Open

Abstract

PURPOSE: To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC). METHODS: Patients with aRCC with a clear cell component were stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk and randomised to NIVO (3 mg/kg) plus IPI (1 mg/kg) every three weeks ×4 doses, followed by NIVO (3 mg/kg) every two weeks; or SUN (50 mg) once per day ×4 weeks (6-week cycle). Efficacy endpoints included overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) per independent radiology review committee in patients with intermediate/poor-risk disease (I/P; primary), intent-to-treat patients (ITT; secondary) and in patients with favourable-risk disease (FAV; exploratory). RESULTS: Overall, 1096 patients were randomised (ITT: NIVO+IPI, n=550, SUN, n=546; I/P: NIVO+IPI, n=425, SUN, n=422; FAV: NIVO+IPI, n=125, SUN, n=124). After 4 years minimum follow-up, OS (HR; 95% CI) remained superior with NIVO+IPI vs SUN in ITT (0.69; 0.59 to 0.81) and I/P patients (0.65; 0.54 to 0.78). Four-year PFS probabilities were 31.0% vs 17.3% (ITT) and 32.7% vs 12.3% (I/P), with NIVO+IPI vs SUN. ORR remained higher with NIVO+IPI vs SUN in ITT (39.1% vs 32.4%) and I/P (41.9% vs 26.8%) patients. In FAV patients, the HRs (95% CI) for OS and PFS were 0.93 (0.62 to 1.40) and 1.84 (1.29 to 2.62); ORR was lower with NIVO+IPI vs SUN. However, more patients in all risk groups achieved complete responses with NIVO+IPI: ITT (10.7% vs 2.6%), I/P (10.4% vs 1.4%) and FAV (12.0% vs 6.5%). Probability (95% CI) of response ≥4 years was higher with NIVO+IPI vs SUN (ITT, 59% (0.51 to 0.66) vs 30% (0.21 to 0.39); I/P, 59% (0.50 to 0.67) vs 24% (0.14 to 0.36); and FAV, 60% (0.41 to 0.75) vs 38% (0.22 to 0.54)) regardless of risk category. Safety remained favourable with NIVO+IPI vs SUN. CONCLUSION: After long-term follow-up, NIVO+IPI continues to demonstrate durable efficacy benefits vs SUN, with manageable safety. TRIAL REGISTRATION DETAILS: ClinicalTrials.gov identifier: NCT02231749.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/esmoopen-2020-001079

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 519

Metadata

Authors
Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, C. K., Gurney, H., Grimm, M.-O., Tomita, Y., Castellano, D., Rini, B. I., Choueiri, T. K., Saggi, S. S., McHenry, M. B., & Motzer, R. J.
Venue
ESMO Open
Publisher
Elsevier BV
Published
2020
Volume
5
Issue
6
Pages
e001079
ISSN
2059-7029 (ISSN-L)
OpenAlex
W3107453141
Cited by
519
References
15
FWCI
42.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. https://app.cochat.ai/papers/10.1136/esmoopen-2020-001079
The paper
Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, C. K., Gurney, H., Grimm, M.-O., Tomita, Y., Castellano, D., Rini, B. I., Choueiri, T. K., Saggi, S. S., McHenry, M. B., & Motzer, R. J. (2020). Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. https://doi.org/10.1136/esmoopen-2020-001079

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.